Site Search

>> Advanced Search

Free Newsletter

  Email address:
   

In the News
Greg Scott presents industry update during JPMorgan
>> View video…

>> More News...

Now on Twitter!
 

Twitter ID: ChinaBio

Sinovac Prospers in Q2 on Large Government Order

publication date: Aug 20, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Sinovac Biotech (北京科兴生物制品有限公司) prospered during its Q2, thanks largely to a single $12.8 million order for its major product, the hepatitis A vaccine Healive®. Sinovac said Q2 revenues were up 21% at $20 million while net income increased a much larger 74% to $5.8 million. Sinovac reported that 89% of the $12.8 million order was filled during Q2. That means $11.4 million of the company’s $20 million in Q2 revenues derived from the one-time event. More details...

Stock Symbol: (NYSE Amex: SVA)

 




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

 

 
   
ChinaBio® Events
April 14, 2010
Guangzhou, China

SEED Final Competion and Award Ceremony
April 23, 2010
Shanghai, China
Suzhou, China
June 23-24, 2010
 
Partner Events

China 2010 Pharmaceutical R&D Summit
Shanghai, China
April 5-8, 2010

Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners